Drug Profile
Cabiralizumab - Bristol-Myers Squibb/Five Prime Therapeutics
Alternative Names: BMS-986227; Cabiralizumab; FPA-008; ONO-4687Latest Information Update: 24 Aug 2023
Price :
$50
*
At a glance
- Originator Five Prime Therapeutics
- Developer Bristol-Myers Squibb; Five Prime Therapeutics; NYU Langone Health; Pyxis Oncology; University of Chicago; University of Michigan Rogel Cancer Center; Yale University
- Class Anti-inflammatories; Antineoplastics; Antirheumatics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Macrophage colony stimulating factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Liver cancer; Pancreatic cancer; Peripheral T-cell lymphoma; Pigmented villonodular synovitis
- Phase I/II Triple negative breast cancer
- No development reported Cancer; Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours
- Discontinued Rheumatoid arthritis
Most Recent Events
- 23 Aug 2023 Apexigen has been acquired and merged into Pyxis Oncology
- 06 Jul 2023 University of Michigan Rogel Cancer Center in collaboration with Bristol-Myers Squibb completes a phase II trial in Peripheral T-cell lymphoma (Combination therapy, Second-line therapy or greater) in USA (IV) (NCT03927105)
- 01 Jun 2023 Bristol-Myers Squibb completes a phase-II trial in Pancreatic cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in Canada, Denmark, Germany, Japan, Italy, Spain, Switzerland, South Korea, Taiwan, USA and United Kingdom (IV) (NCT03336216; EudraCT2018-000339-28)